When you hear the words Alzheimer's disease, what do you think of? The truth is, the picture most of us have of the disease is incomplete. Alzheimer's disease doesn't start when someone starts to lose their memory. It actually starts years – sometimes decades – earlier. The Rethinking Alzheimer's Disease Podcast is an engaging, narrative-style podcast miniseries for those curious or motivated to learn about Alzheimer’s disease. Perhaps you have a family member with Alzheimer’s disease, or ca ...
…
continue reading
Content provided by Dr Neil Love. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Dr Neil Love or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
Player FM - Podcast App
Go offline with the Player FM app!
Go offline with the Player FM app!
Breast Cancer — Microlearning Activity 1 with Dr Priyanka Sharma: 2025 ESMO Annual Meeting Updates
QUICKTIME•Episode home
Manage episode 521336689 series 2530615
Content provided by Dr Neil Love. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Dr Neil Love or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
Featuring an interview with Dr Priyanka Sharma, including the following topics:
- T-DXd versus trastuzumab emtansine for high-risk HER2-positive primary breast cancer with residual invasive disease after neoadjuvant therapy: Interim analysis of the DESTINY-Breast05 trial (0:00)
- Geyer C et al. Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (pts) with high-risk human epidermal growth factor receptor 2–positive (HER2+) primary breast cancer (BC) with residual invasive disease after neoadjuvant therapy (tx): Interim analysis of DESTINY-Breast05. ESMO 2025;Abstract LBA1.
- DESTINY-Breast11 trial: Neoadjuvant T-DXd alone or followed by paclitaxel/trastuzumab/pertuzumab for high-risk HER2-positive localized breast cancer (5:42)
- Harbeck N et al. DESTINY-Breast11: Neoadjuvant trastuzumab deruxtecan alone (T-DXd) or followed by paclitaxel + trastuzumab + pertuzumab (T-DXd-THP) vs SOC for high-risk HER2+ early breast cancer (eBC). ESMO 2025;Abstract 291O.
- Trastuzumab deruxtecan (T-DXd) and pertuzumab versus a taxane, trastuzumab and pertuzumab for HER2-positive advanced or metastatic breast cancer: Additional analyses of the DESTINY-Breast09 trial (10:00)
- Loibl S et al. Trastuzumab deruxtecan (T-DXd) + pertuzumab (P) vs taxane + trastuzumab + pertuzumab (THP) for patients (pts) with HER2+ advanced/metastatic breast cancer (a/mBC): Additional analyses of DESTINY-Breast09 in key subgroups of interest. ESMO 2025;Abstract LBA18.
787 episodes
QUICKTIME•Episode home
Manage episode 521336689 series 2530615
Content provided by Dr Neil Love. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Dr Neil Love or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
Featuring an interview with Dr Priyanka Sharma, including the following topics:
- T-DXd versus trastuzumab emtansine for high-risk HER2-positive primary breast cancer with residual invasive disease after neoadjuvant therapy: Interim analysis of the DESTINY-Breast05 trial (0:00)
- Geyer C et al. Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (pts) with high-risk human epidermal growth factor receptor 2–positive (HER2+) primary breast cancer (BC) with residual invasive disease after neoadjuvant therapy (tx): Interim analysis of DESTINY-Breast05. ESMO 2025;Abstract LBA1.
- DESTINY-Breast11 trial: Neoadjuvant T-DXd alone or followed by paclitaxel/trastuzumab/pertuzumab for high-risk HER2-positive localized breast cancer (5:42)
- Harbeck N et al. DESTINY-Breast11: Neoadjuvant trastuzumab deruxtecan alone (T-DXd) or followed by paclitaxel + trastuzumab + pertuzumab (T-DXd-THP) vs SOC for high-risk HER2+ early breast cancer (eBC). ESMO 2025;Abstract 291O.
- Trastuzumab deruxtecan (T-DXd) and pertuzumab versus a taxane, trastuzumab and pertuzumab for HER2-positive advanced or metastatic breast cancer: Additional analyses of the DESTINY-Breast09 trial (10:00)
- Loibl S et al. Trastuzumab deruxtecan (T-DXd) + pertuzumab (P) vs taxane + trastuzumab + pertuzumab (THP) for patients (pts) with HER2+ advanced/metastatic breast cancer (a/mBC): Additional analyses of DESTINY-Breast09 in key subgroups of interest. ESMO 2025;Abstract LBA18.
787 episodes
Alle afleveringen
×Welcome to Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.